Pfizer

YTD

ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

CEO

Albert Bourla

CEOAlbert Bourla

Employees

81,000

Employees81,000

Headquarters

New York, New York

HeadquartersNew York, New York

Founded

1849

Founded1849

Employees

81,000

Employees81,000

PFE Key Statistics

Market cap

139.77B

Market cap139.77B

Price-Earnings ratio

18.37

Price-Earnings ratio18.37

Dividend yield

6.71%

Dividend yield6.71%

Average volume

40.24M

Average volume40.24M

High today

$25.44

High today$25.44

Low today

$24.53

Low today$24.53

Open price

$25.34

Open price$25.34

Volume

54.46M

Volume54.46M

52 Week high

$31.54

52 Week high$31.54

52 Week low

$20.92

52 Week low$20.92

PFE News

Benzinga 2d

Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlook

Bank of America (BofA) Securities updated the earnings model for Pfizer Inc. PFE. The company will announce second-quarter 2025 earnings on August 5. According...

TipRanks 2d

Pfizer’s RSV Vaccine Trial: A Potential Game-Changer for Infants with HIV

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock...

TipRanks 5d

Pfizer’s Promising Migraine Study in Adolescents: What Investors Should Know

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unl...

Analyst ratings

60%

of 25 ratings

Buy

36%

Hold

60%

Sell

More PFE News

TipRanks 5d

Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: A Potential Game-Changer

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unl...

TipRanks 5d

Pfizer’s New Acne Treatment Study: A Potential Game-Changer?

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unl...

Benzinga 5d

Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony

The Delaware Supreme Court has overturned a lower court’s decision that allowed expert testimony supporting plaintiffs’ claims in a high-profile case alleging t...

TipRanks 6d

Delaware Supreme Court sides with GSK, Pfizer on expert testimony in Zantac case

The Delaware Supreme Court ruled that expert testimony tying Zantac to cancer was not admissible, siding with arguments from GSK (GSK), Pfizer (PFE) and Boehrin...

Benzinga 6d

Pfize, Astellas Report Xtandi Survival Win In Prostate Cancer Study

Pfizer Inc. PFE and Astellas Pharma Inc. ALPMF ALPMY on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study...

TipRanks 6d

Pfizer’s Real-World Study on Abrocitinib for Atopic Dermatitis: Market Implications

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unl...

TipRanks 6d

Pfizer’s New Study on PF-07985045: A Potential Game-Changer in Cancer Treatment?

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unl...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.